It has been proposed that Akt/mammalian target of rapamycin (mTOR) pathway inhibition may sensitize breast cancer cells to doxorubicin (13,14); however, few clinical studies have investigated the association between pAkt expression and the resistance to doxorubicin in breast cancer patients. Here, MTOR is linked to breast carcinoma.